To embed, copy and paste the code into your website or blog:
[author: Stephanie D. Willis]
For insights into how Foreign Corrupt Practices Act (FCPA) enforcement is creeping into the pharmaceutical and medical device manufacturer arena, see this article, which I co-authored with Paul Pelletier, former principal deputy chief of the Criminal Division’s Fraud Section at the Department of Justice (DOJ). It discusses how DOJ is now using “letters of inquiry” and other informal practices to get pharmaceutical companies to report their knowledge of their competitors’ fraudulent activities to the government as a condition of resolving an investigation.
On March 26th, a few days before the article published, another device manufacturer, Biomet, Inc., announced that it entered into a new Deferred Prosecution Agreement (DPA) and accompanying settlements with DOJ and the Securities and Exchange Commission. Coupled with the DPAs DOJ entered into with Johnson & Johnson in April 2011 and Smith & Nephew in February 2012, this announcement signals the fact that DOJ apparenlty is looking beyond United States’ boundaries for health care fraud enforcement opportunities.
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Mintz Levin - Health Law & Policy Matters
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
Back to Top